Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Operating Leases: 2022-2024

Historic Operating Leases for Oncology Institute (TOI) over the last 3 years, with FY2024 value amounting to $23.2 million.

  • Oncology Institute's Operating Leases fell 1291.5% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 1291.5%. This contributed to the annual value of $23.2 million for FY2024, which is 1231.97% down from last year.
  • Latest data reveals that Oncology Institute reported Operating Leases of $23.2 million as of FY2024, which was down 1231.97% from $26.5 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Operating Leases ranged from a high of $26.5 million in FY2023 and a low of $22.1 million during FY2022
  • Moreover, its 3-year median value for Operating Leases was $23.2 million (2024), whereas its average is $23.9 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 2006.35% in 2023, then tumbled by 1231.97% in 2024.
  • Annual analysis of 3 years shows Oncology Institute's Operating Leases stood at $22.1 million in 2022, then rose by 20.06% to $26.5 million in 2023, then fell by 12.32% to $23.2 million in 2024.
  • Its last three reported values are $23.2 million in FY2024, $26.5 million for FY2023, and $22.1 million during FY2022.